|
|
The candidates are expected to:
Deliver high quality software by oneself and together with the team (including design, code, tests, documentation).
Promote high quality engineering of the target solutions.
Embrace Agile practices.
Collaborate with users, functional analysts and deployment team to design fit for purpose software and features.
Specific Assignments:
Contribute to the design, development, troubleshooting, tests and documentation of select functions, at appropriate quality levels, and timely.
Follow and promote development practices and policies compliant with pharmaceutical regulations, in order to produce software functions that can easily be implemented and qualified by users and Quality Assurance.
Use sound software engineering practices and state-of-art development methodologies – so-called Agile – so as to ensure superior quality.
Create and maintain level 3 technical and operational documentation that describes program code, logic, changes, and corrections for assigned functions.
Provide continued level 3 support for select functions. |
|
Good communication and interpersonal relation skills in an international environment.
Pleasant personality, dedicated and driven.
English in speech and in writing is required, Dutch is desirable.
Strong background in Software Development.
Willing to following training and/or studies.
.NET Developer specific skills:
2 - 6 years’ experience in.Net using C# .NET 2008/2010.
Experience with MS SQL Server 2008.
Experience with MVC, Browser based development, Web-services (asmx and/or wcf).
Considered as a plus:
Prior experience in industrial settings and especially with Laboratory processes.
Working knowledge of XML, web services.
Object-Oriented design, programming, and frameworks.
Experience with Clinical Trial Management, Supply Automation, System integration.
Knowledge of Agile methodology.
Experience SharePoint, MEF, MVC with Areas, Modular Web Development.
Experience with Oracle/SQL database design.
Experience with continuous integration methodology. |
|
|
|
|
|
|
|
